Pakistan will fast-track Phase III clinical trials of a new hepatitis delta treatment in collaboration with Chinese firm Huahui Health.
The virus, affecting hepatitis B patients, threatens severe liver disease. Officials aim to ensure affordable access and early diagnosis nationwide.
Partnerships with local pharmaceutical companies will support domestic production, technology transfer, and distribution of life-saving medicines across Pakistan.
Related stories:
OIC COMSTECH Expands Pakistan-China Medicine Cooperation
China’s advancement in biotechnology and traditional medicines benefits Pakistan
